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Gemcitabine monotherapy is considered the standard treatment for inoperable and metalstatic pancreatic cancer, improving overall surl
vival (OS) and offering a statistically significant clinil
cal benefit over the best supportive care. However, the 
overall objective response rate still remains as low as 
10% and the median survival no more than 6 months.1,2 
Over the last years, several studies have introduced new 
combination regimens with or without gemcitabine; 
some combinations have demonstrated a higher or siml
ilar response rate and survival to those of gemcitabine 
monotherapy while platinum containing treatments rel
sult in high toxicity in these patients.3l7 A randomized 
study comparing single agent gemcitabine versus geml
citabine plus weekly 5lfluorouracil (5lFU) showed no 
improvement in median survival.8 There are also trials 
using capecitabine, the oral fluoropyrimidine in combil
nation with gemcitabine achieving similar response and 
survival rates. A small phase II study using biweekly 
gemcitabine, 5lFU and leucovorin showed a promising 
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BACKGROUnD AnD OBJeCTIVe: the response rate and median survival with gemcitabine monotherapy, al-
though considered the standard treatment for inoperable and metastatic pancreatic cancer, is relatively poor. We 
tested the efficacy and toxicity of a chemotherapy protocol consisting of gemcitabine, 5-fluorouracil (5-fu) and 
leucovorin in patients with inoperable or metastatic pancreatic cancer, which was shown to improve median 
survival in a small phase ii trial. 
PATIenTS AnD MeThODS: patients older than 18 years of age with histologically or cytologically confirmed 
adenocarcinoma of the pancreas and bidimensionally measurable disease, and who were chemotherapy- and 
radiotherapy-naïve, were treated with a chemotherapy protocol consisting of gemcitabine 1250 mg/m2 on day 1, 
5-fu 450 mg/m2 and leucovorin 100 mg/m2 on days 1-3. the treatment was repeated every 2 weeks. 
ReSULTS: in an-intention-to-treat analysis, of 37 patients with pancreatic cancer (27 males, 10 females) (67.6% 
stage iVb) there were 7 (18.9%) objective partial responses (95% confidence interval, 8.33% to 29), 14 (37.8%) 
patients had stable disease and 16 (43.2%) had progressive disease. the median response time was 3 months 
(range, 1.5 to 7.0 months). median overall survival time was 6.5 months (range, 1.0 to 15.5 months). the response 
to chemotherapy was not different between males and females (P=.971). no grade iii/iV toxicities were seen. 
COnCLUSIOn: despite our poor survival data, the combination of gemcitabine with 5-fu and leucovorin is an 
active and well-tolerated regimen in patients with pancreatic cancer that merits further evaluation in prospective 
randomized studies. this combination may be considered a valuable alternative to gemcitabine alone.
median survival of 13 months and a very low toxicity 
profile.9 We therefore decided to conduct a phase II 
study using this treatment protocol in our group of adl
vanced stage or metastatic pancreatic cancer patients. 
PATIenTS AnD MeThODS
Patients older than 18 years of age with histologically 
or cytologically confirmed adenocarcinoma of the panl
creas and bidimensionally measurable disease, and who 
were chemotherapyl and radiotherapylnaïve, were enl
rolled in the study. Other eligibility criteria included 
a World Health Organization (WHO) performance 
status (PS) of 0l1, life expectancy of at least 3 months, 
adequate bone marrow reserves (granulocyte count 
≥1500/dL, platelet count ≥120 000/dL), normal renal 
(serum creatinine concentration <1.2 mg/dL) and liver 
function tests, normal cardiac function with no history 
of clinically unstable angina pectoris or myocardial inl
farction, or congestive heart failure within the previous 
6 months, and no central nervous system involvement. 
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Prior surgery was allowed provided it had taken place 
at least 3 weeks before. Patients with active infection, 
malnutrition or a second primary tumor (except for a 
nonlmelanoma skin epithelioma or in situ cervix carcil
noma) were excluded from the study. All patients gave 
written informed consent.
 All patients were treated on an outpatient basis with 
a chemotherapy protocol consisting of gemcitabine 
1000 mg/m2 on day 1, 5lFU 450 mg/m2 and leucovorin 
100 mg/m2 on days 1l3. Cycles were repeated every 14 
days provided that patients had recovered sufficiently 
from the druglrelated side effects. Standard granisetron 
antilemetic treatment was administered to all patients. 
Prophylactic administration of recombinant human 
granulocyte colonylstimulating factor (rhGlCSF) was 
not allowed. Treatment was administered for at least 
four cycles or until disease progression, at the discrel
tion of the physician. After four cycles a CT scan was 
performed. All patients showing a response or stable 
disease were scheduled for a total of eight treatment 
cycles. 
 Pretreatment evaluation included complete medical 
history and physical examination, full blood cell count 
including differential leukocyte and platelet count, a 
standard biochemical profile (and creatinine clearance 
when necessary), electrocardiogram, chest Xlrays, CT 
scans of the upper and lower abdomen. Additional 
imaging studies were performed depending on clinil
cal indication. Full blood counts with differential were 
performed biweekly. A detailed medical and physical 
examination was completed before each course of treatl
ment in order to document symptoms of the disease 
and treatment toxicities. Lesions were evaluated after 
four cycles.
 A complete response (CR) was defined as the disl
appearance of all measurable or evaluable disease, signs 
and symptoms and biochemical changes related to the 
tumor for at least 4 weeks, during which time no new 
lesions may appear. Partial response (PR) was defined 
as >50% reduction in the sum of the products of the 
perpendicular diameters of all measurable lesions coml
pared with pretreatment measurements, lasting for at 
least 4 weeks, during which time no new lesions may 
appear and no existing lesions may enlarge. For hepatic 
lesions, a reduction of >30% in the sum of the meal
sured distances from the costal margin at the midclal
vicular line and at the xiphoid process to the edge of 
the liver was required. Stable disease (SD) was defined 
as <50% reduction and a <25% increase in the sum 
of the products of the two perpendicular diameters of 
all measured lesions and the appearance of no new lel
sions for 8 weeks. Progressive disease (PD) was defined 
as an increase in the product of the two perpendicular 
diameters of any measurable lesion by >25% over the 
size present at entry into the study, or for patients who 
responded, the size at the time of maximum regression 
and the appearance of new areas of malignant disease. 
All responses had to be maintained for at least 4 weeks 
and be confirmed by an independent panel of radiolol
gists. 
 This was an extended, twolstep, phase II study. 
The primary end point of the study was the efficacy of 
the regimen, and the secondary end points were overl
all survival (OS) and tolerance. Duration of response 
was calculated from the day of the first demonstration 
of response until progressive disease. The time to tul
mor progression (TTP) was calculated from the day 
of entry into the study until documented PD. OS was 
calculated from the day of enrollment until death; conl
fidence intervals for response rates were calculated usl
ing methods for the exact binomial confidence interval 
(CI). Comparison of variables was performed using 
the chilsquare test and comparison of means was perl
formed using the chilsquare test .
ReSULTS
From November 2003 until November 2007, 37 pal
tients (27 males, 10 females) were enrolled in this trial. 
All patients were treated at the Special Medical Center 
(a charity hospital) in Tehran. Mean and (SD) for age 
was 54 (12) years (range, 35 to 74 years). Twelve pal
tients had a locally advanced inoperable pancreatic carl
cinoma (stage IIIB) and 25 patients had a metastatic 
disease primarily involving the liver (stage IVb). All pal
tients had a WHO grade 0l1 performance status.
 A total of 228 chemotherapy cycles were adminisl
tered with a median of 6 cycles per patient, ranging from 
2 to 8 and the mean was 6.16 (2.17). Two patients died 
Table 1. patient characteristics (n=37).
age (years)
   mean (SD) 54 (12)
   Range 35-74
Sex, n (%)
   male 27 (73%)
   Female 10 (27%)
Stage of disease, n (%)
   iii 12 (32.4%)
   iV 25 (67.6%)
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before receiving 4 cycles of treatment due to progresl
sion of their disease. Fourteen patients, who showed a 
progression in their CT scan after 4 cycles, had to disl
continue treatment; the other 23 patients received the 
total number of 8 cycles.
 Responses were analyzed on an intentionltoltreat 
basis. There were no complete responses. Of 37 pal
tients, there were 7 (18.9%; 95% CI 8.33% to 29.4%) 
partial responses. Fourteen (37.8%) patients had stable 
disease and 16 (43.2%) had progressive disease. In the 
12 patients with inoperable stage III disease, there were 
4 (33.3%) partial responses. Overall mean survival was 
6.5 months for stage III disease and 5.8 months for 
stage IVb, respectively (P=.345; t test). The response 
to chemotherapy by sex of patients was not significant 
(P=.971) (Table 2). The mean progressionlfree survival 
in female and male was 6.40 (2.24) and 5.85 (2.20) 
months, respectively (P=.508, t test). The response 
to chemotherapy by stage of disease was significant 
(P=.023) (Table 3). The mean progressionlfree survival 
in patients with stages 3 and 4 was 6.50 (2.10) and 5.76 
(2.22) months respectively (P=.345, t test).
Chemotherapy using our protocol was well tolerl
ated, with no grade 3 or 4 toxicities in any of the 37 
patients. Neither of the two fatal events occurring in the 
study were considered drug related.
DISCUSSIOn
The results of the present study seem to indicate that 
the combination of gemcitabine and 5lFU/leucovorin 
is a rather cheap, relatively active and very wellltolerated 
regimen for the treatment of patients with stages III/
IV pancreatic cancer. Although we had unexpectedly 
poor survival data, the 18.9% objective response rate, 
which corresponds to 10 partial responses is worth furl
ther investigation of this protocol. Another 14 patients 
with early stage pancreatic cancer received this protocol 
as their adjuvant chemotherapy at our center with no 
grade 3/4 toxicity. There was no relapse with a median 
follow up of 65 months (data not shown).
Singlelagent gemcitabine therapy has shown marl
ginal objective activity in patients with pancreatic canl
cer and the drug is now considered the treatment of 
choice for this disease based on improvement of quall
ity of life and the clinical benefit in a high percentage 
of patients.1,2 There is still much debate over the curl
rent standard of care in advanced pancreatic cancer. 
Apart from the UK GemCap trial,10 other phase III 
studies have shown no significant OS advantage for 
gemcitabine plus capecitabine,11 5lFU4,8 irinotecan5 
cisplatin12 or oxaliplatinhttp://jco.ascopubs.org/cgi/
content/full/25/16/2212 l R10#R1013 compared 
with gemcitabine alone. A recent phase III trial with 
gemcitabine, 5lFU and leucovorin, while using a differl
ent schedule, showed no survival advantage versus the 
use of gemcitabine alone.14
The pooled analysis of the GERCOR/GISCAD 
intergroup study and the German multicenter study 
indicated that the combination of gemcitabine with 
a platinum analog such as oxaliplatin or cisplatin sigl
nificantly improves progressionlfree survival (PFS) 
and OS as compared to singlelagent gemcitabine in 
advanced pancreatic cancer. The benefit seemed to prel
vail in patients with a good PS. For PFS, the pooled 
univariate analysis indicated a hazard ratio (HR) of 
0.75 (P=.0030) in favor of the gemcitabinelplatinum 
combination. Median survival was 8.3 v 6.7 months, 
respectively (P=.031 and PFS 5.5 v 3.5 months, rel
spectively; P=.003).11
Another recent metalanalysis of randomized tril
als indicated a significant survival benefit when geml
citabine was either combined with platinum analogs or 
fluoropyrimidines. Based on a preliminary subgroup 
analysis (representing 38% of all patients included in 
this metalanalysis), pancreatic cancer patients with a 
good PS appeared to benefit from gemcitabinelbased 
cytotoxic combinations, whereas patients with a poor 
PS seem to had no survival benefit from combination 
chemotherapy.15 The only other agent to have shown 
a survival benefit when added to gemcitabine is erlol
tinib.16 Overall survival was significantly prolonged on 
the erlotinib/gemcitabine arm with a hazard ratio of 
0.82 (95% CI, 0.69 to 0.99; P=.038). Onelyear surl
vival was also greater with erlotinib plus gemcitabine 
Table 2. The response to chemotherapy by sex of patient.
Response (n, %)
Total
PR SD PD
Female 2 (20.0) 4 (40.0) 4  (40.0) 10  
male 5  (18.5) 10  (37.0) 12  (44.4) 27   
Total 7  (18.9) 14  (37.8) 16  (43.2) 37 
pR: partial remission, SD: stable disease, pD: persistent disease
Table 3. The response to chemotherapy by stage of disease.
Response (n, %)
Total
PR SD PD
Stage iii 4  (33.3) 6  (50.0) 2  (16.7) 12  
Stage iV 3 (12.0) 8  (32.0) 14  (56.0) 25  
Total 7  (18.9) 14  (37.8) 16  (43.2) 37  
pR: partial remission, SD: stable disease, pD: persistent disease
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(23% v 17%; P=.023). 
 In conclusion, the results of our study indicate that 
the combination of gemcitabine and 5lFU/leucovorin, 
although no breakthrough in terms of survival, may be 
considered a valuable alternative to gemcitabine alone 
for the treatment of patients with advanced/metastatic 
pancreatic cancer and can be considered for further tril
als in combination with erlotinib.
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